Miguel Villalona A MD, FACP

Miguel Villalona A MD, FACP
ProfessorCollege of Medicinevillalona.1@osu.edu
A455A Starling Loving Hall 320 W 10th Avenue Columbus Ohio 43210
Phone:614-366-5068Fax: (614) 293-7520
  • Translational Therapeutics

Research Description

Dr. Villalona applies novel therapeutic agents with diverse targets and translates his observations into solid tumor therapy. He has pioneered clinical and research teams that evaluated many novel cytotoxic agents. With a specific focus on solid tumors such as lung cancer, Dr. Villalona has studied diverse molecules, cell signaling pathways, and transcription regulators involved in cancer progression and maintenance.

Current Publications

  • Phelps MA, Stinchcombe TE, Blachly JS, Zhao W, Schaaf LJ, Starrett SL, Wei L, Poi M, Wang D, Papp A, Aimiuwu J, Gao Y, Li J, Otterson GA, Hicks WJ, Socinski MA, Villalona-Calero MAErlotinib in african americans with advanced non-small cell lung cancer: a prospective randomized study with genetic and pharmacokinetic analyses.Clin Pharmacol Ther 96 182-91 8/1/2014
  • Woods G, Sebastian N, Fabian D, Kaplon R, Hammond S, Palanichamy K, Chakravarti A, Houghton PJ, Singh M, Leasure JM, Chronowski C, Geier B, Bondra K, Duan W, Hensley LA, Villalona-Calero M, Li N, Vergis AM, Kurmasheva RT, Shen CFANCD2 is a potential therapeutic target and biomarker in alveolar rhabdomyosarcoma harboring the PAX3-FOXO1 fusion gene.Clin Cancer Res 20 3884-95 7/15/2014
  • Chen W, Brodsky SV, Zhao W, Otterson GA, Villalona-Calero M, Satoskar AA, Hasan A, Pelletier R, Ivanov I, Ross P, Nadasdy T, Shilo KY-chromosome status identification suggests a recipient origin of posttransplant non-small cell lung carcinomas: chromogenic in situ hybridization analysis.Hum Pathol 45 1065-70 5/1/2014
  • Grenade C, Phelps MA, Villalona-Calero MARace and ethnicity in cancer therapy: what have we learned?Clin Pharmacol Ther 95 403-12 4/1/2014
  • Imielinski M, Greulich H, Kaplan B, Araujo L, Amann J, Horn L, Schiller J, Villalona-Calero MA, Meyerson M, Carbone DPOncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma.J Clin Invest 124 1582-6 4/1/2014
  • Heist RS, Wang X, Hodgson L, Otterson GA, Stinchcombe TE, Gandhi L, Villalona-Calero MA, Watson P, Vokes EE, Socinski MA, Alliance for Clinical Trials in OncologyCALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer.J Thorac Oncol 9 214-21 2/1/2014
  • Zhao W, Yilmaz A, Mohamed N, Patterson KA, Tang Y, Shilo K, Villalona-Calero MA, Davis ME, Zhou XP, Frankel W, Otterson GAClinical and Metabolic Parameters in Non-Small Cell Lung Carcinoma and Colorectal Cancer Patients with and without KRAS Mutations.Int J Environ Res Public Health 11 8645-60 1/1/2014
  • Yilmaz A, Mohamed N, Patterson KA, Tang Y, Shilo K, Villalona-Calero MA, Davis ME, Zhou X, Frankel W, Otterson GA, Beall HD, Zhao WIncreased NQO1 but Not c-MET and Survivin Expression in Non-Small Cell Lung Carcinoma with KRAS Mutations.Int J Environ Res Public Health 11 9491-502 1/1/2014
  • Wu C, Fernandez SA, Criswell T, Chidiac TA, Guttridge D, Villalona-Calero M, Bekaii-Saab TSDisrupting cytokine signaling in pancreatic cancer: a phase I/II study of etanercept in combination with gemcitabine in patients with advanced disease.Pancreas 42 813-8 7/1/2013
  • Haraldsdottir S, Li Q, Villalona-Calero MA, Olencki TE, Kendra K, Ing SWCase of sorafenib-induced thyroid storm.J Clin Oncol 31 e262-4 6/1/2013
  • Duan W, Gao L, Zhao W, Leon M, Sadee W, Webb A, Resnick K, Wu X, Ramaswamy B, Cohn DE, Shapiro C, Andreassen PR, Otterson GA, Villalona-Calero MAAssessment of FANCD2 nuclear foci formation in paraffin-embedded tumors: a potential patient-enrichment strategy for treatment with DNA interstrand crosslinking agents.Transl Res 161 156-64 3/1/2013
  • Wu X, Upadhyaya P, Villalona-Calero MA, Briesewitz R, Pei DInhibition of Ras-Effector Interaction by Cyclic Peptides.Medchemcomm 4 378-382 2/1/2013
  • Chu BF, Karpenko MJ, Liu Z, Aimiuwu J, Villalona-Calero MA, Chan KK, Grever MR, Otterson GAPhase I study of 5-aza-2'-deoxycytidine in combination with valproic acid in non-small-cell lung cancer.Cancer Chemother Pharmacol 71 115-21 1/1/2013
  • Shilo K, Wu X, Sharma S, Welliver M, Duan W, Villalona-Calero M, Fukuoka J, Sif S, Baiocchi R, Hitchcock CL, Zhao W, Otterson GACellular localization of protein arginine methyltransferase-5 correlates with grade of lung tumors.Diagn Pathol 8 201 1/1/2013
  • Bertino EM, Bekaii-Saab T, Fernandez S, Diasio RB, Karim NA, Otterson GA, Villalona-Calero MAA phase II study of modulated-capecitabine and docetaxel in chemonaive patients with advanced non-small cell lung cancer (NSCLC).Lung Cancer 79 27-32 1/1/2013
  • Wang H, Chen P, Wang J, Santhanam R, Aimiuwu J, Saradhi UV, Liu Z, Schwind S, Mims A, Byrd JC, Grever MR, Villalona-Calero MA, Klisovic R, Walker A, Garzon R, Blum W, Chan KK, Marcucci GIn vivo quantification of active decitabine-triphosphate metabolite: a novel pharmacoanalytical endpoint for optimization of hypomethylating therapy in acute myeloid leukemia.AAPS J 15 242-9 1/1/2013

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 460 W. 10th Avenue, Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu